Arbutus Biopharma (NASDAQ:ABUS) – Analysts at William Blair issued their Q1 2019 EPS estimates for shares of Arbutus Biopharma in a research note issued to investors on Thursday, March 15th, according to Zacks Investment Research. William Blair analyst Y. Xu expects that the biopharmaceutical company will earn ($0.46) per share for the quarter. William Blair also issued estimates for Arbutus Biopharma’s Q2 2019 earnings at ($0.46) EPS, Q3 2019 earnings at ($0.47) EPS and Q4 2019 earnings at ($0.66) EPS.
Arbutus Biopharma (NASDAQ:ABUS) last posted its quarterly earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.51). Arbutus Biopharma had a negative net margin of 796.23% and a negative return on equity of 55.28%. The firm had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $0.70 million.
ABUS has been the subject of a number of other research reports. Chardan Capital reissued a “buy” rating on shares of Arbutus Biopharma in a research report on Tuesday, January 16th. ValuEngine raised Arbutus Biopharma from a “sell” rating to a “hold” rating in a research report on Thursday, March 15th. Zacks Investment Research downgraded Arbutus Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, January 18th. BidaskClub downgraded Arbutus Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, February 24th. Finally, Wedbush downgraded Arbutus Biopharma from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $9.00 to $6.00 in a research report on Monday, March 19th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. Arbutus Biopharma currently has a consensus rating of “Hold” and an average price target of $12.38.
ABUS stock traded up $0.05 during trading on Friday, reaching $5.05. 140,028 shares of the stock traded hands, compared to its average volume of 217,476. Arbutus Biopharma has a 52-week low of $3.20 and a 52-week high of $8.25. The company has a current ratio of 8.85, a quick ratio of 8.85 and a debt-to-equity ratio of 0.09. The company has a market cap of $278.10, a PE ratio of -2.82 and a beta of 1.06.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Millennium Management LLC boosted its position in shares of Arbutus Biopharma by 309.1% in the fourth quarter. Millennium Management LLC now owns 82,007 shares of the biopharmaceutical company’s stock worth $414,000 after buying an additional 61,961 shares during the period. Two Sigma Investments LP acquired a new position in shares of Arbutus Biopharma in the fourth quarter worth about $215,000. Goldman Sachs Group Inc. acquired a new position in shares of Arbutus Biopharma in the fourth quarter worth about $275,000. Deutsche Bank AG lifted its stake in shares of Arbutus Biopharma by 24.8% in the fourth quarter. Deutsche Bank AG now owns 163,451 shares of the biopharmaceutical company’s stock worth $825,000 after acquiring an additional 32,451 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Arbutus Biopharma by 150.7% in the fourth quarter. Renaissance Technologies LLC now owns 402,573 shares of the biopharmaceutical company’s stock worth $2,033,000 after acquiring an additional 241,963 shares in the last quarter. 62.12% of the stock is owned by institutional investors.
WARNING: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/08/arbutus-biopharma-abus-expected-to-earn-q1-2019-earnings-of-0-46-per-share.html.
About Arbutus Biopharma
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Get a free copy of the Zacks research report on Arbutus Biopharma (ABUS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.